한글목차

세계의 동반진단 시장은 2025년 87억 6,000만 달러로 추정되었으며, 2032년까지 197억 3,000만 달러에 이를 것으로 예측됩니다. 2025년부터 2032년까지 연평균 복합 성장률은(CAGR) 12.3%로 성장할 것으로 전망되고 있습니다.

동반진단은 특정 치료법에 가장 적합한 환자를 결정하는 데 도움이 되는 환자에서 특정 바이오마커 및 유전자를 검출하는 데 사용되는 의료 기기입니다. 이러한 진단은 의사가 암 및 기타 질병에 대한 적절한 표적 치료를 선택하도록 지원함으로써 개인화된 건강 관리에서 중요한 역할을 합니다. 동반진단 검사는 특정 약물에 대한 환자의 반응에 관여하는 단백질, 유전자, 염색체 등의 바이오마커의 발현을 평가합니다. 이러한 바이오마커의 발현 수준을 분석하면 특정 질병이 있는 특정 환자 또는 환자 그룹에 대해 특정 약물이 안전하고 효과적인지 여부를 결정할 수 있습니다. 이렇게 하면 적절한 환자만 전문적인 치료를 받을 수 있어 치료 결과를 향상시킬 수 있습니다.

시장 역학

세계의 동반진단 시장은 맞춤형 의료에 대한 수요 증가, 분자진단 기술의 성장, 신규 표적 요법 및 동반진단의 승인 확대, 기술 진보, 암 및 기타 만성 질환의 발생률 및 유병률의 상승에 의해 견인되고 있습니다. 그러나 이러한 분자진단 검사의 개발 및 상업화에 따른 고가격 압력과 규제상의 번잡함이 시장 성장의 제약 요인이 될 수 있습니다. 본 시장의 주요 기회로는 면역요법용 바이오마커 및 동반진단의 개발, 비 암 질환 분야에 응용 확대, 체외 진단약(IVD) 기업과 제약 기업간의 정밀의료 분야 제휴, 신흥 시장에서의 동반진단 개발에 대한 주목 상승, 바이오 마커 검출을 위한 차세대 시퀀싱(NGS) 등이 있습니다.

본 조사의 주요 특징

• 이 보고서는 세계의 동반진단 시장에 대한 상세한 분석을 제공하며, 2024년을 기준 연도로 예측 기간 중(2025-2032년) 시장 규모(10억 달러) 및 CAGR(%)을 보여줍니다.
• 또한 각 부문에서 잠재적인 수익 기회를 밝히고 이 시장의 매력적인 투자 제안 매트릭스에 대해 설명합니다.
• 본 조사에서는 시장 성장 촉진요인, 시장 성장 억제요인, 기회, 신제품의 발매 또는 승인, 시장 동향, 지역별 전망, 주요 기업이 채용하는 경쟁 전략에 관한 중요한 인사이트도 제공합니다.
• 이 보고서는 다음 매개 변수를 기반으로 세계의 동반진단 시장에서 주요 기업 프로파일을 제시합니다 - 기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적 및 전략
• 이 보고서의 인사이트는 마케팅 담당자와 기업 경영진이 향후 제품 출시, 유형 업그레이드, 시장 확대 및 마케팅 전략에 대한 정보를 기반으로 의사 결정을 내릴 수 있도록 합니다.
• 세계의 동반진단 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진출기업, 금융 분석가 등 이 업계의 다양한 이해관계자를 지원합니다.
• 이해관계자는 세계의 동반진단 시장 분석에 이용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 할 수 있게 됩니다.

목차

제1장 조사 목적과 전제조건

• 조사 목적
• 전제조건
• 약어

제2장 시장 범위

• 보고서 개요
  • 시장 정의와 범위
• 주요 요약
• Coherent Opportunity Map(COM)

제3장 시장 역학, 규제 및 동향 분석

• 시장 역학
  • 암 환자 수 증가
  • 통합의 복잡성
  • 신흥 시장
• 주요 하이라이트
• 규제 환경
• 최근 동향
• 제품 발매 및 승인 상황
• PEST 분석
• Porter's Five Forces 분석
• 합병, 인수 및 제휴

제4장 세계의 동반진단 시장 : 기술 유형별, 2020-2032년

• 실시간 중합효소 연쇄반응(PCR)
• 유전자 시퀀싱
• 형광 제자리 부합법(FISH)
• 기타

제5장 세계의 동반진단 시장 : 용도별, 2020-2032년

• 종양학
• 심혈관 질환
• 감염증
• 신경질환
• 기타

제6장 세계의 동반진단 시장 : 최종 사용자별, 2020-2032년

• 병원
• 연구기관
• 바이오의약품 기업
• 기타

제7장 세계의 동반진단 시장 : 지역별, 2020-2032년

• 북미
  • 미국
  • 캐나다
• 유럽
  • 독일
  • 영국
  • 스페인
  • 프랑스
  • 이탈리아
  • 러시아
  • 기타 유럽
• 아시아태평양
  • 중국
  • 인도
  • 일본
  • 호주
  • 한국
  • ASEAN
  • 기타 아시아태평양
• 라틴아메리카
  • 브라질
  • 아르헨티나
  • 멕시코
  • 기타 라틴아메리카
• 중동
  • GCC 국가
  • 이스라엘
  • 기타 중동 국가
• 아프리카
  • 남아프리카
  • 북아프리카
  • 중앙 아프리카

제8장 경쟁 구도

• 기업 프로파일
  • F.Hoffmann-La Roche AG
  • Agilent Technologies, Inc
  • QIAGEN NV
  • Abbott Laboratories, Inc.
  • Almac Group
  • Danaher Corporation
  • Illumina, Inc
  • bioMerieux SA
  • Myriad Genetics, Inc
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc
  • Abnova Corporation
  • Guardant Health, Inc.
  • Icon Plc
  • Biogenex Laboratories, Inc

제9장 섹션

• 참고문헌
• 조사 방법
• 당사에 대해

영문목차

Companion Diagnostics Market is estimated to be valued at USD 8.76 Bn in 2025 and is expected to reach USD 19.73 Bn by 2032, growing at a compound annual growth rate (CAGR) of 12.3% from 2025 to 2032.

Companion diagnostics are medical devices that are used to detect specific biomarkers or genes in patients that help determine which patients are most suitable candidates for a particular therapy. These diagnostics play an important role in personalized healthcare by helping physicians select appropriate targeted treatment options for cancer and other diseases. Companion diagnostics tests evaluate the expression of biomarkers, such as proteins, genes or chromosomes that plays a role in a patient's response to a specific drug. By analyzing the expression levels of such biomarkers, these tests help to identify whether a particular drug would be safe and effective for a specific patient or set of patients with a given disease. This enables better therapeutic outcomes by ensuring only suitable patients receive specialized treatments.

Market Dynamics

Global companion diagnostics market is driven by rising demand for personalized medicine, growth in molecular diagnostics, increasing approvals of new targeted therapies & companion diagnostics, technological advancements, and growing incidence and prevalence of cancer, and other chronic diseases. However, the market growth can be restricted by high pricing pressure and regulatory hassles that are involved in developing and commercializing these molecular diagnostic tests. Key opportunities in this market include developing biomarkers and companion diagnostics for immunotherapies, expanding applications in non-oncology diseases, precision medicine collaborations between In vitro diagnostics (IVD) companies and drug makers, growing focus on companion diagnostic development in emerging markets, and adoption of advanced technologies like Next-generation sequencing (NGS) for biomarker detection.

Key features of the study

• This report provides in-depth analysis of the global companion diagnostics market, and provides market size (USD Bn)and compound annual growth rate (CAGR %) for the forecast period 2025-2032, considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global companion diagnostics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include F. Hoffmann-La Roche AG, Agilent Technologies, Inc., QIAGEN N.V, Abbott Laboratories, Inc., Almac Group, Danaher Corporation, Illumina, Inc., bioMerieux SA, Myriad Genetics, Inc., Sysmex Corporation, Thermo Fisher Scientific Inc., Abnova Corporation, Guardant Health, Inc., Icon Plc., and Biogenex Laboratories, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global companion diagnostics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global companion diagnostics market

Market Segmentation

• By Technology Type
  • Real Time-Polymerase Chain Reactions (PCR)
  • Gene Sequencing
  • Fluorescence in situ Hybridization
  • Others
• By Application
  • Oncology
  • Cardiovascular Diseases
  • Infectious Diseases
  • Neurological Diseases
  • Others
• By End User
  • Hospitals
  • Research Laboratories
  • Biopharmaceutical companies
  • Others
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • Hoffmann-La Roche AG
  • Agilent Technologies, Inc
  • QIAGEN N.V
  • Abbott Laboratories, Inc.
  • Almac Group
  • Danaher Corporation
  • Illumina, Inc.
  • bioMerieux SA
  • Myriad Genetics, Inc.
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Abnova Corporation
  • Guardant Health, Inc.
  • Icon Plc.,
  • Biogenex Laboratories, Inc.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Technology Type
  • Market Snippet, By Application
  • Market Snippet, By End User
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Increasing number of cancer patients
  • Complexity of Integration
  • Emerging markets
• Key Highlights
• Regulatory Scenario
• Recent Trends
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Mergers, Acquisitions and Collaborations

4. Global Companion Diagnostics Market, By Technology Type, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Real Time-Polymerase Chain Reactions (PCR)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Gene Sequencing
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Fluorescence in situ Hybridization
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Companion Diagnostics Market, By Application, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Oncology
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Cardiovascular Diseases
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Infectious Diseases
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Neurological Diseases
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Companion Diagnostics Market, By End User, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospitals
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Research Laboratories
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Biopharmaceutical companies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Companion Diagnostics Market, By Region, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2021 -2032
  • Country Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Technology Type, 2020-2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (USD Bn)
    • U.S.
    • Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Technology Type, 2020-2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Technology Type, 2020-2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Technology Type, 2020-2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Technology Type, 2020-2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Technology Type, 2020-2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032, (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

8. Competitive Landscape

• Company Profiles
  • F.Hoffmann-La Roche AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Agilent Technologies, Inc
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • QIAGEN N.V
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Abbott Laboratories, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Almac Group
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Danaher Corporation
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Illumina, Inc
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • bioMerieux SA
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Myriad Genetics, Inc
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Sysmex Corporation
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Thermo Fisher Scientific Inc
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Abnova Corporation
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Guardant Health, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Icon Plc
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Biogenex Laboratories, Inc
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
    • Analysts' Views

9. Section

• References
• Research Methodology
• About us